Theravance Biopharma Ireland

Company snapshot

Theravance Biopharma Ireland maintains 57 tracked programs across Pulmonary Disease, Chronic Obstructive, Symptomatic Neurogenic Orthostatic Hypertension, Chronic Obstructive Pulmonary Disease, COPD, Chronic Obstructive Pulmonary Disease, COPD, Gastroparesis, Symptomatic Neurogenic Orthostatic Hypotension, Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19), Crohn's Disease, Acute L

• 2 approved product(s) across US/EU regulatory metadata.
• 57 active pipeline program(s) linked via ClinicalTrials.gov.
• 635 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Theravance Biopharma Ireland. Not investment advice.

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Theravance Biopharma Ireland.

1. Jun 8, 2026 Clinical update

   velusetrag dose 1 — Phase 2

2. Jun 8, 2026 Clinical update

   TD-1211 Dose 1 — Phase 1

3. Jun 8, 2026 Clinical update

   Revefenacin Inhalation Solution [Yupelri] — Phase 2

4. Jun 8, 2026 Clinical update

   400 microgrammes GSK961081 — Phase 2

5. Jun 5, 2026 Clinical update

   Velusetrag — Phase 2

View all clinical trial activity →

• What is Theravance Biopharma Ireland?

  Theravance Biopharma Ireland is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker TBPH. Primary therapeutic focus areas include Pulmonary Disease, Chronic Obstructive, Symptomatic Neurogenic Orthostatic Hypertension, Chronic Obstruct

• Is Theravance Biopharma Ireland publicly traded?

  Yes. Theravance Biopharma Ireland is listed with ticker TBPH on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Theravance Biopharma Ireland develop or market?

  We link 18 drug profile(s) where Theravance Biopharma Ireland is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/theravance-biopharma#company-drugs.

• What are the latest developments for Theravance Biopharma Ireland?

  In the last 12 months our linked public records show 57 trial program update(s) and 3 US patent grant(s) tied to this profile.

• What therapeutic areas does Theravance Biopharma Ireland focus on?

  Theravance Biopharma Ireland focuses on Pulmonary Disease, Chronic Obstructive, Symptomatic Neurogenic Orthostatic Hypertension, Chronic Obstructive Pulmonary Disease, COPD based on our analysis of their pipeline programs and drug development activities.